文献速递新生儿儿童呼吸

经喉罩与气管插管给予肺表面活性物质的随机试验

Randomized Trial of Surfactant Therapy via Laryngeal Mask Airway Versus Brief Tracheal Intubation in Neonates Born Preterm.
PubMed 文献 · J Pediatr · 2022-10-12

该随机对照试验纳入胎龄27至36周、出生体重>800 g、诊断RDS且经无创呼吸支持接受FiO2 0.30-0.60的早产儿,比较经喉罩(LMA)与气管插管(ETT)给予肺表面活性物质避免机械通气的非劣效性。结果显示LMA组失败率20%、ETT组29%(P=.311),LMA非劣效于ETT,且早期失败(1小时内)LMA组2%低于ETT组12.5%(P=.044)。

要点

  • 经喉罩给予肺表面活性物质在避免机械通气方面非劣效于经气管插管。
  • LMA组早期失败(1小时内)2%,低于ETT组的12.5%(P=.044)。
  • 两组在降低FiO2、给药次数、脱离呼吸支持时间及不良事件上无差异。

核心结论

  • 经喉罩给予肺表面活性物质非劣效于经气管插管,且可能通过避免预用药、喉镜和插管的不良反应减少早期失败。

研究设计与样本

  • 随机对照试验,纳入胎龄27至36周、出生体重>800 g、诊断RDS且经无创呼吸支持接受FiO2 0.30-0.60的早产儿,随机分入LMA组(51例)和ETT组(42例)。

主要发现

  • 主要结局失败率ETT组29%、LMA组20%(P=.311),失败风险差-9.0%(CI -∞至5.7%)。
  • 早期失败(1小时内)ETT组12.5%、LMA组2%(P=.044)。
  • 两组在降低FiO2、肺表面活性物质给药次数、脱离所有呼吸支持时间、不良事件率及气胸和BPD诊断等结局上无差异。

关键数值与推荐

  • LMA组采用阿托品预用药,ETT组采用InSuRE方法并予阿托品和瑞芬太尼预用药。
  • 主要结局为肺表面活性物质治疗失败导致需要机械通气。

临床怎么用

  • 对于符合纳入标准的早产RDS患儿,经喉罩给予肺表面活性物质可作为经气管插管的替代途径。

局限性

  • 样本量较小(LMA组51例、ETT组42例),非劣效性检验的置信区间上限较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the possible noninferiority of surfactant administration via laryngeal mask airway (LMA) vs endotracheal tube (ETT) in avoiding the requirement for mechanical ventilation in preterm neonates with respiratory distress syndrome (RDS). STUDY DESIGN: This was a randomized controlled trial including infants born at 27 to 36 weeks of gestation, >800 g, diagnosed with RDS and receiving fraction of inspired oxygen 0.30-0.60 via noninvasive respiratory support. Infants were randomized to surfactant via LMA (with atropine premedication) or ETT (InSuRE approach with atropine and remifentanil premedication). Primary outcome was failure of surfactant treatment to prevent the need for mechanical ventilation. RESULTS: Patients were randomized, 51 to LMA and 42 to the ETT group. Both groups had similar baseline characteristics, with birth weights ranging from 810 to 3560 g. Failure rate was 29% in the ETT group and 20% in the LMA group (P = .311). This difference was due to early failures (within 1 hour), with 12.5% in the ETT group and 2% in the LMA group (P = .044). Surfactant therapy via LMA was non-inferior to administration via ETT; failure risk difference -9.0% (CI -∞ to 5.7%). Efficacy in decreasing fraction of inspired oxygen, number of surfactant doses administered, time to wean off all respiratory support, rates of adverse events, and outcomes including pneumothorax and BPD diagnosis did not differ between groups. CONCLUSIONS: Surfactant therapy via LMA was noninferior to administration via ETT and it decreased early failures, possibly by avoiding adverse effects of premedication, laryngoscopy, and intubation. These characteristics make LMA a desirable conduit for surfactant administration. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02164734.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Gallup JA, Ndakor SM, Pezzano C, et al. Randomized Trial of Surfactant Therapy via Laryngeal Mask Airway Versus Brief Tracheal Intubation in Neonates Born Preterm. J Pediatr. 2022. PMID: 36241051. doi:10.1016/j.jpeds.2022.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。